Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 28, Issue 13, Pages 8884-8891Publisher
SPRINGER
DOI: 10.1245/s10434-021-10307-4
Keywords
-
Funding
- William and Susan Johnson Fund for Endocrine Surgery Research
Ask authors/readers for more resources
Despite the challenges in managing thyroid nodules, molecular testing platforms have been developed to improve cancer risk assessment for patients with cytologically indeterminate nodules, and have been incorporated into guidelines as an important diagnostic adjunct. Numerous studies have demonstrated the accuracy and utility of molecular testing in the contemporary management of thyroid nodules.
Despite advances in imaging and biopsy techniques, the management of thyroid nodules often remains a diagnostic and clinical challenge. In particular, patients with cytologically indeterminate nodules often undergo diagnostic thyroidectomy although only a minority of patients are found to have thyroid malignancy on final pathology. More recently, several molecular testing platforms have been developed to improve the stratification of cancer risk for patients with cytologically indeterminate thyroid nodules. Based on numerous studies demonstrating its accuracy, molecular testing has been incorporated as an important diagnostic adjunct in the management of indeterminate thyroid nodules in the National Comprehensive Cancer Network Guidelines as well as in the American Thyroid Association (ATA) and American Association of Endocrine Surgeons (AAES) guidelines. This overview describes the currently available molecular testing platforms and highlights the published data to date on the clinical validity and utility of molecular testing in the contemporary management of thyroid nodules.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available